Home Tags NCT02631876

Tag: NCT02631876

ImmunoGen and FDA Discuss Ongoing Development for Mirvetuximab Soravtansine

The United States Food and Drug Administration (FDA) has recommended that ImmunoGen conducts a new Phase III randomized trial to evaluate the safety and...

FEATURED RESOURCES